STOCK TITAN

[Form 4] Twist Bioscience Corp Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4

Robert F. Werner, Chief Accounting Officer and director of Twist Bioscience Corp (TWST), reported a non-discretionary sale of 2,041 shares of common stock on 10/06/2025 at a price of $32.187 per share. After the sale, Mr. Werner beneficially owned 46,413 shares. The filing states the shares were sold to satisfy tax-withholding obligations tied to the vesting of Performance Stock Units (PSUs) and were executed under the issuer's mandatory "sell to cover" election, not as voluntary open-market trades. The Form 4 was signed by an attorney-in-fact on 10/08/2025.

Robert F. Werner, Chief Accounting Officer e direttore di Twist Bioscience Corp (TWST), ha riportato una vendita non discrezionale di 2.041 azioni ordinarie il 06/10/2025 a un prezzo di $32.187 per azione. Dopo la vendita, il signor Werner deteneva beneficamente 46.413 azioni. Il deposito indica che le azioni sono state vendute per soddisfare gli obblighi di ritenuta fiscale legati al vesting delle Performance Stock Units (PSUs) e sono state eseguite nell ambito dell elezione obbligatoria dell emittente vendere per coprire, non come operazioni volontarie in mercato aperto. Il Form 4 è stato firmato da un procuratore-in-fatto il 08/10/2025.
Robert F. Werner, Director de Contabilidad y director de Twist Bioscience Corp (TWST), informó de una venta no discrecional de 2.041 acciones ordinarias el 06/10/2025 a un precio de $32.187 por acción. Después de la venta, el Sr. Werner poseía beneficialmente 46.413 acciones. La presentación indica que las acciones se vendieron para satisfacer obligaciones de retención de impuestos vinculadas al vesting de las Unidades de Acciones de Desempeño (PSUs) y se ejecutaron bajo la elección obligatoria de la empresa de vender para cubrir, no como operaciones voluntarias en el mercado abierto. El Formulario 4 fue firmado por un apoderado en poder el 08/10/2025.
로버트 F. 워너(Robert F. Werner) 회계 최고 책임자이자 Twist Bioscience Corp(TWST) 이사의 비재량적 매도 보고가 2025년 10월 6일 주당 32.187달러에 2,041주를 매도했다고 밝혔다. 매도 후 워너 이사는 실질적으로 46,413주를 보유하게 되었다. 신고서에 의하면 매도 주식은 성과주식단위(PSU)의 취득 시점에 따른 세금 원천징수 의무를 충당하기 위해 팔렸으며, 발행사가 의무적으로 채택한 판매로커에 의한 매도 선택에 따라 실행되었으며, 자발적 공개시장 거래가 아니었다고 한다. 4 Form은 2025년 10월 8일에 대리인이 서명했다.
Robert F. Werner, directeur financier et administrateur de Twist Bioscience Corp (TWST), a signalé une vente non discrétionnaire de 2 041 actions ordinaires le 06/10/2025 à un prix de 32,187 $ par action. Après la vente, M. Werner détenait bénévolement 46 413 actions. Le dossier indique que les actions ont été vendues pour satisfaire les obligations de retenue d'impôt liées à l'acquisition des unités d'actions de performance (PSU) et ont été exécutées dans le cadre de l option obligatoire de vendre pour couvrir de l émetteur, et non comme des transactions volontaires sur le marché libre. Le Formulaire 4 a été signé par un mandataire à la date du 08/10/2025.
Robert F. Werner, Chief Accounting Officer und Vorstandsmitglied der Twist Bioscience Corp (TWST), meldete einen nicht diskretionären Verkauf von 2.041 Stammaktien am 06.10.2025 zu einem Preis von 32,187 $ pro Aktie. Nach dem Verkauf besaß Herr Werner wirtschaftliches Eigentum an 46.413 Aktien. Die Einreichung besagt, dass die Aktien verkauft wurden, um Steuerabzugsverpflichtungen im Zusammenhang mit dem Vesting von Performance Stock Units (PSUs) zu erfüllen, und sie unterlagen der obligatorischen Sell-to-Cover-Wahl des Emittenten, nicht als freiwillige Trades im offenen Markt. Das Formular 4 wurde von einem Bevollmächtigten am 08.10.2025 unterschrieben.
أبلغ روبرت ف. ويرنر، كبير مسؤولي المحاسبة ومدير شركة Twist Bioscience Corp (TWST)، عن بيع غير تقديري لـ2,041 سهماً من الأسهم العادية في 06/10/2025 بسعر 32.187 دولاراً للسهم. بعد البيع، امتلك السيد ويرنر فعلياً 46,413 سهماً. تشير الوثيقة إلى أن الأسهم بيعت لسد الالتزامات الضريبية المتعلقة بالتجهيزات الناشئة عن استحقاق وحدات الأسهم للأداء (PSUs) وتم تنفيذها بموجب خيار بيع لتغطية إلزامي من قبل المصدر، وليس كصفقات سوق مفتوح طوعية. تم توقيع النموذج 4 من قبل نائب مفوض في 08/10/2025.
罗伯特·F·沃纳尔, Twist Bioscience Corp(TWST)的首席会计官兼董事,报告称在2025年10月6日以每股32.187美元的价格非自由裁量权出售了2,041股普通股。出售后,沃纳尔先生实际持有46,413股。申报文件称,出售股票是为满足与绩效股票单位(PSU)归属相关的税收预扣义务而进行的,并且是在发行方强制性的“卖出以覆盖”选项下执行的,而不是自愿的公开市场交易。Form 4由代理人于2025年10月8日签署。
Positive
  • Insider retained significant ownership with 46,413 shares remaining after the transaction
  • Sale was non-discretionary and executed to satisfy tax withholding from PSU vesting
Negative
  • []

Insights

Sale was a routine "sell-to-cover" for vested PSUs, not a discretionary trade.

The transaction shows 2,041 shares sold at $32.187 to meet tax withholding from vested Performance Stock Units. A "sell to cover" is a common mechanism where the employer elects to satisfy tax obligations by selling a portion of vested equity.

This reduces the reporting person's outstanding shares by the stated amount and has no disclosed change to ongoing equity incentive terms; monitor upcoming equity vesting schedules and any future Form 4s around scheduled PSU vesting dates within the next 12 months.

Insider remains materially invested with post-sale ownership intact.

After the transaction the reporting person retained 46,413 shares, indicating continued ownership alignment with shareholders. The Form 4 identifies the transaction as directed by the issuer's tax-withholding election, limiting interpretive weight about intent.

Investors often view sell-to-cover differently from discretionary selling; watch for any future reported sales that are not labeled as tax-withholding within the next fiscal year to assess changes in insider conviction.

Robert F. Werner, Chief Accounting Officer e direttore di Twist Bioscience Corp (TWST), ha riportato una vendita non discrezionale di 2.041 azioni ordinarie il 06/10/2025 a un prezzo di $32.187 per azione. Dopo la vendita, il signor Werner deteneva beneficamente 46.413 azioni. Il deposito indica che le azioni sono state vendute per soddisfare gli obblighi di ritenuta fiscale legati al vesting delle Performance Stock Units (PSUs) e sono state eseguite nell ambito dell elezione obbligatoria dell emittente vendere per coprire, non come operazioni volontarie in mercato aperto. Il Form 4 è stato firmato da un procuratore-in-fatto il 08/10/2025.
Robert F. Werner, Director de Contabilidad y director de Twist Bioscience Corp (TWST), informó de una venta no discrecional de 2.041 acciones ordinarias el 06/10/2025 a un precio de $32.187 por acción. Después de la venta, el Sr. Werner poseía beneficialmente 46.413 acciones. La presentación indica que las acciones se vendieron para satisfacer obligaciones de retención de impuestos vinculadas al vesting de las Unidades de Acciones de Desempeño (PSUs) y se ejecutaron bajo la elección obligatoria de la empresa de vender para cubrir, no como operaciones voluntarias en el mercado abierto. El Formulario 4 fue firmado por un apoderado en poder el 08/10/2025.
로버트 F. 워너(Robert F. Werner) 회계 최고 책임자이자 Twist Bioscience Corp(TWST) 이사의 비재량적 매도 보고가 2025년 10월 6일 주당 32.187달러에 2,041주를 매도했다고 밝혔다. 매도 후 워너 이사는 실질적으로 46,413주를 보유하게 되었다. 신고서에 의하면 매도 주식은 성과주식단위(PSU)의 취득 시점에 따른 세금 원천징수 의무를 충당하기 위해 팔렸으며, 발행사가 의무적으로 채택한 판매로커에 의한 매도 선택에 따라 실행되었으며, 자발적 공개시장 거래가 아니었다고 한다. 4 Form은 2025년 10월 8일에 대리인이 서명했다.
Robert F. Werner, directeur financier et administrateur de Twist Bioscience Corp (TWST), a signalé une vente non discrétionnaire de 2 041 actions ordinaires le 06/10/2025 à un prix de 32,187 $ par action. Après la vente, M. Werner détenait bénévolement 46 413 actions. Le dossier indique que les actions ont été vendues pour satisfaire les obligations de retenue d'impôt liées à l'acquisition des unités d'actions de performance (PSU) et ont été exécutées dans le cadre de l option obligatoire de vendre pour couvrir de l émetteur, et non comme des transactions volontaires sur le marché libre. Le Formulaire 4 a été signé par un mandataire à la date du 08/10/2025.
Robert F. Werner, Chief Accounting Officer und Vorstandsmitglied der Twist Bioscience Corp (TWST), meldete einen nicht diskretionären Verkauf von 2.041 Stammaktien am 06.10.2025 zu einem Preis von 32,187 $ pro Aktie. Nach dem Verkauf besaß Herr Werner wirtschaftliches Eigentum an 46.413 Aktien. Die Einreichung besagt, dass die Aktien verkauft wurden, um Steuerabzugsverpflichtungen im Zusammenhang mit dem Vesting von Performance Stock Units (PSUs) zu erfüllen, und sie unterlagen der obligatorischen Sell-to-Cover-Wahl des Emittenten, nicht als freiwillige Trades im offenen Markt. Das Formular 4 wurde von einem Bevollmächtigten am 08.10.2025 unterschrieben.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
WERNER ROBERT F.

(Last) (First) (Middle)
C/O TWIST BIOSCIENCE CORPORATION
681 GATEWAY BLVD

(Street)
SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Accounting Officer
3. Date of Earliest Transaction (Month/Day/Year)
10/06/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/06/2025 S 2,041(1) D $32.187 46,413 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Performance Stock Units ("PSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
Remarks:
/s/ Kendra Fox, as Attorney-in-Fact for Robert F. Werner 10/08/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Robert F. Werner report on Form 4 for TWST?

He reported a sale of 2,041 shares on 10/06/2025 at $32.187 per share and a post-transaction beneficial ownership of 46,413 shares.

Why were the 2,041 shares sold according to the filing?

The filing states the shares were sold to satisfy tax withholding obligations related to the vesting of Performance Stock Units (PSUs) under the issuer's mandatory "sell to cover" election.

Was this a discretionary open-market sale?

No. The filing specifies the sale was required by the issuer's election to fund tax withholding and did not represent a discretionary trade by the reporting person.

How much did the shares sell for on 10/06/2025?

The reported sale price was $32.187 per share.

Who signed the Form 4 for Robert F. Werner?

The Form 4 was signed by an attorney-in-fact, Kendra Fox, on 10/08/2025.
Twist Bioscience

NASDAQ:TWST

TWST Rankings

TWST Latest News

TWST Latest SEC Filings

TWST Stock Data

1.88B
59.19M
1.86%
115.89%
16.96%
Diagnostics & Research
Biological Products, (no Disgnostic Substances)
Link
United States
SOUTH SAN FRANCISCO